Of interest for future studies will be to confirm the in vivo effects of BTKi on the different subsets of B cells, T cells and myeloid cell in patients with MS, as well as elucidate whether B cells or myeloid cells are the main mediators of BTKi’s ability to modulate disease-relevant T-cell responses in vivo. The gene discussed is IBTK; the disease is myeloid sarcoma.